Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Related content

Powered by UNSILO

Suggested reading

Bang LM, Goa KL. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 2004; 18: 57–61.
Beniczky SA, Viken J, Jensen LT, Andersen NB. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012; 21: 471–472.
Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC. Antiepileptic drugs and bone metabolism in children: data from 128 patients. Journal of Child Neurology 2013; 28: 176–183.
Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. Journal of the European Academy of Dermatology and Venereology 2009; 23: 702–703.
Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67: 1497–1499.
Gelisse P, Genton P, Kuate D, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282–1288.
Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 2011; 20: 160–162.
Johannessen Landmark S, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.
Patsalos PN. Antiepileptic drug interactions: a clinical guide, 2nd edition. 2013, Springer, London, UK; 2013.
Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Therapeutic Drug Monitoring 2013; 35: 4–29.
Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier JC, Jungers P. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. European Journal of Clinical Pharmacology 1994; 47: 161–167.
Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy & Behavior 2004; 5: 627–635.
Shellhaas RA, Barks AK, Joshi SM. Prevalence and risk factors for vitamin D insufficiency among children with epilepsy. Pediatric Neurology 2010; 42: 422–426.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45: 1330–1337.
Zheng T, Clarke AL, Morris MJ, Reid CA, Petrou S, O’Brien TJ. Oxcarbazepine, not its active metabolite, potentiates GABA A activation and aggravates absence seizures. Epilepsia 2009; 50: 83–87.